Menopause leaves an array of women struggling as they attempt to manage symptoms brought about by the hormonal changes. Furthermore, health issues associated with bone mineral density and circulatory health emerge, making their lives even more challenging. Resveratrol is among the supplements that have over the years been used to address these issues. Among its benefits to postmenopausal women is its mechanism of action on the body’s estrogen receptors.
Resveratrol is a phytoestrogen. This classification means that it can bind to the estrogen receptors in the body. During menopause, estrogen levels diminish, resulting in many symptoms that affect body systems and the quality of life. The supplement fills the gap caused by reduced estrogen levels in postmenopausal women by balancing the processes that estrogen would typically carry out. Consequently, resveratrol improves how postmenopausal women feel, perform and look. These aspects enhance their quality of life. Moreover, investigations have elucidated that the supplement mitigates some of the most common health issues faced by menopausal women.
The Resveratrol for Healthy Ageing Women (RESHAW) trial that occurred over 12 months assessed the health benefits of taking 75mg of Veri-term resveratrol twice a day versus the symptoms that persisted while taking a placebo in postmenopausal women. The findings indicated that the supplements improved bone density in postmenopausal women. Research suggests that postmenopausal women are more susceptible to fractures in their lumbar spines and hips. About 43% of all hospitalizations of older women result from broken bones due to poor mineral density. The RESHAW determined that the uptake of Veri-teTM resveratrol supplementation improves bone density in the lumbar spine and the neck of the femur when compared to the placebo.
Women taking resveratrol showed a reduction in the usual markers of bone degradation. Moreover, the improvement in the bone mineral density in the neck of the femur reduced the risk of suffering a hip fracture by ten years. This outcome suggests significant potential for the supplement to slow bone loss in postmenopausal women, primarily when used with vitamin D.
Estrogen’s role in the flexibility of endothelial tissues lining the circulatory system is critical. The reduction of its levels predisposes women to poor circulatory tissues repair. This outcome causes tissues to stiffen, an aspect that may lead to cognitive decline. In the RESHAW investigation, women taking the Veri-teTM resveratrol supplement showed consistent improvement in their cognitive performance. Additionally, those over 65 years of age indicated improvement in their verbal memory recollection.
Poor endothelial tissue maintenance is also associated with cardiovascular risks in postmenopausal women. Resveratrol’s positive effects on endothelial tissues mean that cardiovascular health is also improved. In a study, 19 postmenopausal women and obese men living with untreated high blood pressure were given three doses of resveratrol or a placebo per week. Subsequently, the resveratrol group showed marked improvement in their blood pressure markers.
During the RESHAW study, women taking the Veri-teTM resveratrol supplement showed a significant reduction in their bone turnover. This outcome signified reduced pain and improved bone mass. Moreover, they exhibited improved mood, sleep, and cognitive function. Therefore, these findings deduce that the supplement improves the overall quality of life in postmenopausal women. Nevertheless, postmenopausal women have continued to experience weight gain that usually arises from poor insulin control. Preliminary research of resveratrol’s effect on type 2 diabetes has shown possible improvements in blood sugar and insulin levels. These results suggest that the supplement may be applied in the future to manage weight gain in postmenopausal women
